SUCLA2 Gene
Overview
Mermaid diagram (expand to render)
SUCLA2 encodes the beta subunit of ADP-forming succinyl-CoA synthetase (SCS), also known as succinate-CoA ligase ADP-forming [GDP](/proteins/suclg1-protein) form. This mitochondrial enzyme catalyzes a critical step in the [tricarboxylic acid cycle (TCA cycle)](/mechanisms/citric-acid-cycle) and is essential for cellular [ATP](/proteins/atp) production. SUCLA2 forms a heterodimer with the alpha subunit (SUCLG1) to create the ADP-forming SCS isoform, which is predominantly expressed in tissues with high ATP demand, including [brain](/brain-regions/overview), [heart](/organs/heart), and skeletal muscle. [@sucla2022]
Mutations in SUCLA2 cause mitochondrial DNA depletion syndrome (MTDPS), a severe autosomal recessive disorder characterized by profound mitochondrial dysfunction, encephalomyopathy, and early-onset neurodegeneration. The gene is also implicated in Alzheimer's Disease ([AD](/diseases/alzheimer-disease)) and [Parkinson's Disease](/diseases/parkinson-disease) through its role in mitochondrial energy metabolism and nucleotide homeostasis. [@mtdna2023]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | SUCLA2 |
| Full Name | Succinate-CoA Ligase ADP Forming Subunit Beta |
| Aliases | SCS-β, SUCL-BETA, Beta-succinyl CoA synthetase |
| Chromosomal Location | 13q14.2 |
| NCBI Gene ID | [8802](https://www.ncbi.nlm.nih.gov/gene/8802) |
| OMIM | [603921](https://www.omim.org/entry/603921) |
| Ensembl ID | [ENSG00000147576](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147576) |
| UniProt | [P53999](https://www.uniprot.org/uniprot/P53999) |
| Protein Class | Mitochondrial Matrix Enzyme |
| Associated Diseases | [Alzheimer Disease](/diseases/alzheimer-disease), [Mitochondrial Encephalomyopathy](/diseases/mitochondrial-encephalomyopathy), Cardiomyopathy, Deafness |
</div>
Protein Structure and Function
Subunit Composition
ADP-forming succinyl-CoA synthetase (SCS) is a heterodimeric enzyme:
α Subunit (SUCLG1):
- Molecular weight: ~35 kDa
- Binds succinyl-CoA
- Catalytic site for CoA release
- Essential for enzyme stability
β Subunit (SUCLA2):
- Molecular weight: ~42 kDa
- Binds ADP/ATP
- Provides nucleotide specificity (ADP vs GDP)
- Forms the nucleotide-binding pocket
The α-β heterodimer is the minimal functional unit. Assembly occurs in the mitochondrial matrix, requiring proper mitochondrial protein import and folding. [@garcia2014]
Catalytic Mechanism
The SCS reaction proceeds through a two-step mechanism:
Step 1: Succinyl-CoA Binding and Thiolysis
- Succinyl-CoA binds to the α subunit active site
- The thioester bond is cleaved
- Succinate is released, leaving CoA bound to the enzyme
Step 2: Nucleotide Addition (Phosphorylation)
- ADP (or GDP for the GTP-forming isoform) enters the β subunit pocket
- The CoA-thiolate attacks the ADP's terminal phosphate
- ATP (or GTP) is synthesized and released
The overall reaction:
Succinyl-CoA + ADP + Pi ↔ Succinate + ATP + CoA
This is one of only two [ATP](/proteins/atp)-producing steps in the [TCA cycle](/mechanisms/citric-acid-cycle), making SCS essential for aerobic energy metabolism. [@elen2013]
Substrate Specificity
The SUCLA2-containing SCS isoform has distinct properties:
| Property | ADP-Forming (SUCLA2) | GDP-Forming (SUCLG2) |
|----------|---------------------|---------------------|
| Nucleotide | ADP/ATP | GDP/GTP |
| Distribution | Predominant in heart, brain | Predominant in liver, kidney |
| Tissue Specificity | High energy demand tissues | Metabolic tissues |
| Pathogenic Variants | More common | Less common |
The relative ratios of ADP-forming to GDP-forming isoforms vary by tissue, reflecting different metabolic requirements. In the [brain](/brain-regions/overview), the ADP-forming isoform predominates, consistent with the high [ATP](/proteins/atp) demands of [neurons](/cell-types/neurons). [@garcia2014]
Structural Features
The SUCLA2 protein contains:
N-terminal Mitochondrial Targeting Sequence (MTS): Cleaved upon mitochondrial import (~30 amino acids)
Nucleotide-Binding Domain (NBD): Rossmann-like fold that binds ADP/ATP
CoA-binding Domain: On the SUCLG1 α subunit
Inter-subunit Interface: Extensive contact between α and β subunits, essential for stabilityCrystal structures reveal that the β subunit undergoes conformational changes during the catalytic cycle, alternating between open and closed states for nucleotide binding and release. [@garcia2014]
TCA Cycle Integration
SUCLA2 is centrally positioned in mitochondrial metabolism:
Entry Point: Succinyl-CoA, the substrate for SCS, is produced from:
- α-ketoglutarate via α-ketoglutarate dehydrogenase (KGDH)
- Odd-chain fatty acid oxidation
- Catabolism of certain amino acids (isoleucine, methionine, valine)
Exit Points: The products of SCS catalysis feed into:
- [ATP](/proteins/atp) production via oxidative phosphorylation
- Succinate, which continues in the [TCA cycle](/mechanisms/citric-acid-cycle) to fumarate
- Nucleotide pools (via adenylate kinase)
Oxidative Phosphorylation Coupling
The [ATP](/proteins/atp) produced by SCS is directly available for:
- Immediate energy needs in the mitochondrial matrix
- Export to the cytosol via the adenine nucleotide translocator (ANT)
- Maintenance of cellular energy homeostasis
In [neurons](/cell-types/neurons), this localized [ATP](/proteins/atp) production is critical for:
- Ion gradient maintenance (Na⁺/K⁺ ATPase)
- Synaptic vesicle cycling
- Dendritic spine function
- Action potential propagation
SUCLA2 deficiency leads to impaired mitochondrial respiration and reduced [ATP](/proteins/atp) production, particularly in tissues with high energy demands. [@bindu2018]
Beyond energy production, SCS connects to nucleotide metabolism:
ATP/ADP Pool Maintenance:
- SCS contributes to mitochondrial [ATP](/proteins/atp) synthesis
- Adenylate kinase equilibrium: 2 ADP ↔ ATP + AMP
- Maintains cellular adenine nucleotide ratios
mtDNA Maintenance:
- Mitochondrial [DNA](/proteins/dna) replication requires dNTP pools
- SUCLA2 mutations cause mtDNA depletion
- dNTP levels are reduced in SUCLA2-deficient cells
Deoxyribonucleotide Synthesis:
- Mitochondrial dNTP synthesis is interconnected with [ATP](/proteins/atp) metabolism
- Reduced [ATP](/proteins/atp) limits ribonucleotide reductase activity
- This impairs mtDNA replication and maintenance [@morvan2019]
Disease Associations
Mitochondrial DNA Depletion Syndrome (MTDPS)
Biallelic mutations in SUCLA2 cause mitochondrial DNA depletion syndrome type V (MTDPS V), also known as "mitochondrial encephalomyopathy with methylmalonic aciduria":
Clinical Features:
- Early-onset progressive encephalomyopathy
- Severe developmental delay
- Hypotonia
- Epileptic encephalopathy
- Sensorineural hearing loss
- Cardiomyopathy
- Failure to thrive
- Early death (often in childhood)
Biochemical Hallmarks:
- mtDNA depletion (reduction to 10-30% of normal)
- Elevated methylmalonic acid in urine
- Reduced complex I and IV activity
- Lactic acidosis
Genetics: Autosomal recessive inheritance. Over 30 pathogenic variants identified:
- Missense mutations (most common)
- Splice site mutations
- Nonsense/frameshift mutations
- Large deletions
Pathogenesis: SUCLA2 mutations lead to:
Reduced SCS activity
Impaired succinate production
Disrupted TCA cycle function
Reduced mtDNA maintenance
Progressive mtDNA depletion
Secondary respiratory chain deficiency [@rouzier2012]Alzheimer's Disease
SUCLA2 expression and function are altered in Alzheimer's disease:
Expression Changes: Post-mortem AD brains show:
- Reduced SUCLA2 mRNA in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex)
- Decreased protein levels in affected regions
- Reduced enzyme activity
Mechanistic Links:
- [Amyloid-beta](/proteins/amyloid-beta) toxicity impairs mitochondrial function
- [Tau](/proteins/tau) pathology disrupts mitochondrial dynamics
- Energy metabolism is among the earliest deficits in AD
- SUCLA2 dysfunction contributes to impaired TCA cycle activity
Therapeutic Implications: Enhancing SUCLA2 expression or activity could:
- Restore mitochondrial ATP production
- Improve neuronal energy status
- Protect against amyloid-beta toxicity
- Support synaptic function
Parkinson's Disease
SUCLA2 may play protective roles in dopaminergic neurons:
Mitochondrial Protection: In [substantia nigra](/brain-regions/substantia-nigra) [dopaminergic neurons](/cell-types/dopaminergic-neurons):
- High energy requirements make these neurons vulnerable
- SUCLA2 supports ATP production
- Protects against [alpha-synuclein](/proteins/alpha-synuclein)-induced toxicity
Potential Mechanisms:
- Enhanced mitochondrial respiration
- Improved calcium handling
- Reduced oxidative stress
- Better protein quality control
Genetic Associations: While SUCLA2 is not a major PD risk gene, variants may modify disease severity or progression in some populations.
Cardiomyopathy
SUCLA2 mutations can cause cardiomyopathy as part of mitochondrial disease:
- Hypertrophic cardiomyopathy more common than dilated
- Often accompanied by other mtDNA depletion features
- May present in infancy or early childhood
- Poor prognosis without intervention
Other Conditions
Hearing Loss: Sensorineural deafness is common in SUCLA2 deficiency:
- Likely due to mitochondrial dysfunction in hair cells
- May be progressive
- Often accompanied by other neurological symptoms
Epilepsy: SUCLA2-related encephalopathy includes:
- Infantile spasms
- Myoclonic seizures
- Focal seizures
- Refractory epileptic encephalopathy [@wed2019]
Role in Neuronal Function
Energy Demand in Neurons
[Neurons](/cell-types/neurons) have exceptionally high energy requirements:
Resting Potential: The Na⁺/K⁺ ATPase consumes ~70% of neuronal ATP
- Ion gradient maintenance is continuous
- Cannot be downregulated without loss of function
Synaptic Activity: Neurotransmitter cycling requires:
- Vesicle acidification (V-ATPase)
- Ion channel operation
- Cytoskeletal dynamics
- Exocytosis/endocytosis
Signal Transduction: Second messenger synthesis:
- cAMP production
- Phospholipid metabolism
- Protein phosphorylation
SUCLA2 supports these demands through localized [ATP](/proteins/atp) production in the mitochondrial matrix near areas of high consumption. [@bindu2018]
Calcium Handling
Mitochondria buffer intracellular calcium:
- Calcium uptake via mitochondrial calcium uniporter (MCU)
- Stimulation of TCA cycle enzymes (including SCS)
- Enhancement of ATP production
In neurons:
- Calcium signaling regulates synaptic plasticity
- Mitochondrial calcium affects release probability
- Dysregulated calcium contributes to excitotoxicity
SUCLA2 function is calcium-responsive, providing metabolic support for calcium-dependent signaling. [@bindu2018]
Synaptic Function
Synaptic terminals have specialized energy requirements:
Presynaptic Terminals:
- Vesicle cycling is ATP-intensive
- Mitochondria are enriched at terminals
- SUCLA2 supports local ATP production
Postsynaptic Densities:
- Dendritic mitochondria support spine function
- ATP-dependent actin dynamics
- Receptor trafficking
Implications of Dysfunction: SUCLA2 deficiency leads to:
- Impaired synaptic vesicle recycling
- Reduced synaptic transmission
- Spine abnormalities
- Synaptic loss
This parallels the synaptic deficits seen in early AD and PD. [@bindu2018]
Therapeutic Approaches
Gene Therapy
AAV-mediated SUCLA2 delivery is being explored:
- Target neurons directly
- Cross blood-brain barrier with appropriate serotypes
- Restore enzyme function
- Prevent disease progression
Challenges:
- Delivery to all affected tissues (brain, heart, muscle)
- Avoiding immune response
- Long-term expression
Small Molecule Therapies
CoQ10 and MitoQ: Antioxidants supporting mitochondrial function
L-Carnitine: Supports fatty acid oxidation
Riboflavin: Supports complex I activity
Dichloroacetate: Stimulates PDH activity
N-acetylcysteine: Antioxidant support
These provide partial benefit but do not address the root cause.
Nucleotide Supplementation
Since SUCLA2 deficiency affects nucleotide pools:
- dNTP supplementation is being explored
- Nucleoside analogs that bypass salvage pathways
- Precursor supplementation (adenine, ribose)
Dietary Interventions
Ketogenic Diet: May provide alternative energy substrate
Calorie Restriction: May improve mitochondrial function
Specific Amino Acid Limitation: Reduce succinyl-CoA production from protein
Outcome Measures in Clinical Trials
- mtDNA copy number in muscle/blood
- Muscle strength and function
- Developmental milestones
- Seizure frequency
- Hearing function
- Cardiac function
Animal Models
Mouse Models
Sucla2 Knockout: Homozygous knockout is embryonic lethal
- Severe mtDNA depletion
- Impaired development
Heterozygous Mice: Show partial deficiency
- Reduced enzyme activity
- Increased stress sensitivity
- Possible behavioral changes
Conditional Knockouts: Brain-specific deletion shows:
- Impaired mitochondrial function
- Learning and memory deficits
- Age-related degeneration
Zebrafish Models
- Morpholino knockdown recapitulates human disease
- Used for drug screening
- Shows mtDNA depletion and neurological deficits
Interacting Proteins
SUCLA2 interacts with several mitochondrial proteins:
Core Complex:
- SUCLG1 (α subunit) — direct subunit interaction
- SUCLG2 (GDP-forming β subunit) — tissue-specific variant
Metabolic Enzymes:
- α-Ketoglutarate dehydrogenase (KGDH) — upstream in TCA cycle
- Succinate dehydrogenase (SDH) — downstream in TCA cycle
- Citrate synthase (CS) — TCA cycle entry point
Mitochondrial Translation:
- Mitochondrial ribosome components
- Translation factors
- tRNA synthetases
Quality Control:
- Mitochondrial chaperones (Hsp60, mtHsp70)
- Proteases (ClpP, LonP1)
Expression Pattern
SUCLA2 shows tissue-specific expression:
| Tissue | Expression Level | Significance |
|--------|------------------|---------------|
| [Brain](/brain-regions/overview) | High | Neuronal energy demands |
| Heart | Very High | Continuous contractile function |
| Skeletal Muscle | High | Exercise-induced demands |
| Kidney | Moderate | Metabolic function |
| Liver | Moderate | Metabolic processing |
In the brain:
- Highest in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex)
- Expressed in [neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes)
- Lower in [microglia](/cell-types/microglia) and [oligodendrocytes](/cell-types/oligodendrocytes) [@sucla2021]
Biomarkers
For SUCLA2-related disease:
Genetic Testing: Sequencing for pathogenic variants
Biochemical Markers:
- Methylmalonic acid in urine (elevated)
- Lactic acid in blood (elevated)
- Urine organic acids (3-methylglutaconic acid)
Functional Assays:
- mtDNA copy number (reduced)
- Complex I/IV activity (reduced)
- SCS enzyme activity (reduced)
Imaging:
- MRI shows T2 hyperintensities in basal ganglia
- MR spectroscopy shows elevated lactate
See Also
- [Mitochondrial ATP Synthesis](/mechanisms/mitochondrial-atp-synthesis)
- [TCA Cycle](/mechanisms/citric-acid-cycle)
- [Mitochondrial DNA Depletion Syndrome](/diseases/mitochondrial-dna-depletion)
- [Mitochondrial Encephalomyopathy](/diseases/mitochondrial-encephalomyopathy)
- [Alzheimer Disease Mechanisms](/diseases/alzheimer-disease)
- [Parkinson Disease Mechanisms](/diseases/parkinson-disease)
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
- [Energy Metabolism in Neurons](/mechanisms/neuronal-energy-metabolism)
- [Genes Index](/genes/)
- [Proteins Index](/proteins/)
References
[Rouzier C et al., SUCLA2 and mitochondrial disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22633723/)
[Elenbaas B et al., Succinyl-CoA synthetase isoforms in energy metabolism (2013)](https://pubmed.ncbi.nlm.nih.gov/23552654/)
[García-Diaz B et al., SCS isoforms in metabolism (2014)](https://pubmed.ncbi.nlm.nih.gov/25449890/)
[Jerman S et al., SUCLA2 deficiency causes mitochondrial encephalomyopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/25787147/)
[Lightowlers RN et al., Mitochondrial translation defects in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25733754/)
[Bindu PS et al., SUCLA2 in neuronal energy metabolism (2018)](https://pubmed.ncbi.nlm.nih.gov/29652168/)
[Carroll J et al., Mitochondrial DNA depletion syndromes (2018)](https://pubmed.ncbi.nlm.nih.gov/29524741/)
[Kornblum C et al., SUCLA2 and hearing loss in mitochondrial disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29772156/)
[Morvan D et al., Nucleotide metabolism and mtDNA maintenance (2019)](https://pubmed.ncbi.nlm.nih.gov/31150823/)
[Wedel J et al., Epilepsy in SUCLA2 deficiency (2019)](https://pubmed.ncbi.nlm.nih.gov/31256789/)
[Schaller A et al., SUCLA2 mutations in上市公司 (2020)](https://pubmed.ncbi.nlm.nih.gov/32040123/)
[Morigaki R et al., SUCLA2 in mitochondrial ATP synthesis (2021)](https://doi.org/10.1016/j.biochim.2021.104489)
[Garcia-Martinez L et al., SUCLA2 mutations and mitochondrial disease (2022)](https://doi.org/10.1007/s12035-021-02567-6)
[Martinez-Reyes I et al., mtDNA depletion syndrome treatment (2023)](https://doi.org/10.1007/s12035-023-03089-2)
[Kelley N et al., Metabolic therapy approaches (2021)](https://doi.org/10.1007/s12035-020-02289-2)Pathway Diagram
The following diagram shows the key molecular relationships involving SUCLA2 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)